此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder

2026年9月4日 更新者：Jonathan Santoro

The goal of this clinical trial is to evaluate whether the monoclonal antibody ublituximab can treat Down Syndrome Regression Disorder (DSRD) by assessing its safety, tolerability, and preliminary efficacy in affected individuals. This study is conducted in adults aged 18-40 years with Down syndrome who have DSRD and have had an inadequate or partial response to first-line therapies.

The main questions it aims to answer are:

  • Does ublituximab demonstrate acceptable safety and tolerability, as measured by treatment-emergent adverse events from baseline through Week 24?
  • Does ublituximab lead to improvement in cognitive, neuropsychiatric, motor, and functional outcomes from baseline to Weeks 12 and 24?

This is a single-arm study, so there is no comparison group.

Participants will:

  • Receive two intravenous infusions of ublituximab (150 mg on Day 1 and 450 mg on Day 15)
  • Attend study visits at Screening, Baseline (Day 1) , Week 2 (Day 15), Week 3, Week 6, Week 12, and Week 24
  • Undergo clinical assessments, including neurological and physical exams and safety monitoring labs throughout the study
  • Complete cognitive, behavioral, and functional evaluations at Baseline, Week 12, and Week 24
  • Provide blood samples for safety monitoring and research biomarker analyses

研究概览

地位

尚未招聘

条件

干预/治疗

研究类型

介入性

注册 (估计的)

20

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

  • 美国
    • California
      • Los Angeles、California、美国、90027
        • Children's Hospital Los Angeles
        • 接触：
        • 接触：
        • 首席研究员：
          • Jonathan Santoro, MD

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

不

描述

Inclusion Criteria:

  • Age 18 to 40 years, inclusive at time of consent
  • Diagnosis of Down syndrome (trisomy 21 or translocation type)
  • Diagnosis of possible or probable Down Syndrome Regression Disorder (DSRD) based on 2022 International Consensus Criteria
  • History of partial response or non-response to first-line treatment (e.g., lorazepam, SSRIs, corticosteroids, and/or IVIg). Partial response = 10-50% improvement, Non-response = <10% improvement, Based on BFCRS or NPI-Q after 3 months of treatment.
  • Ability to attend all study visits with a study partner or legally authorized representative
  • Study partner willing to comply with all study procedures
  • Willingness to complete required washout periods for medications that may interfere with the study
  • Highly effective contraception for reproductive participants and partners of childbearing potential.
  • Study partner/LAR sufficiently proficient in English to complete assessments.

Exclusion Criteria:

  • Mosaic Down syndrome
  • Weight < 40 kg at screening
  • Pregnancy or breastfeeding
  • Current or past tobacco smoking
  • Poor venous access or inability to comply with IV procedures
  • Use of IVIg within 8 weeks prior to baseline
  • Use of immunosuppressive drugs within 12 weeks prior to baseline
  • Prior treatment with anti-CD20 or B-cell therapies within required washout unless B-cell recovery criteria are met
  • Other immunosuppressive biologics within 24 months.
  • Any prior use of chemotherapeutic agents (e.g., methotrexate, cyclophosphamide)
  • History of solid organ transplant
  • Recent receipt of blood or plasma products (≤30 days)
  • Clinically significant cardiac disease, clotting disorder, or other serious medical condition
  • Active or chronic infection of clinical significance (including HBV, HCV, TB, HIV per protocol criteria)
  • History of malignancy
  • Abnormal screening labs indicating unacceptable risk
  • Receipt of live or live-attenuated vaccines within 4 weeks prior to treatment
  • Untreated thyroid disease (hypo- or hyperthyroidism)
  • History of moyamoya syndrome or stroke
  • Wards of the state
  • Employees or students of Children's Hospital Los Angeles (CHLA)
  • Prior neurosurgical intervention (exceptions for longstanding shunts)
  • Current investigational therapy/prohibited medications
  • Detailed HBV, HCV, and TB criteria
  • Requirement for B-cell recovery >50 cells/μL after prior anti-CD20 therapy.

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：治疗
  • 分配：不适用
  • 介入模型：单组作业
  • 屏蔽：无（打开标签）

武器和干预

参与者组/臂
干预/治疗
实验性的：Ublituximab
Participants assigned to the Ublituximab arm will receive a fixed two-dose intravenous regimen consisting of 150 mg on Day 1 and 450 mg on Day 15. All participants will be followed for 24 weeks with regular safety monitoring, clinical assessments, and evaluation of cognitive, neuropsychiatric, and functional outcomes.
药品：Ublituximab
Participants assigned to the Ublituximab arm will receive a fixed two-dose intravenous regimen consisting of 150 mg on Day 1 and 450 mg on Day 15. All participants will be followed for 24 weeks with regular safety monitoring, clinical assessments, and evaluation of cognitive, neuropsychiatric, and functional outcomes.

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Total AEs on Ublituximab
大体时间：Baseline through Week 24
Safety will be evaluated by the incidence, type, severity (graded per CTCAE v5.0), and relationship of treatment-emergent adverse events (AEs) occurring after the first dose of ublituximab. Tolerability will be assessed by the proportion of participants completing both doses and follow-up without dose modifications, interruptions, or discontinuation due to AEs.
Baseline through Week 24

次要结果测量

结果测量
措施说明
大体时间
Change in Scores for Adaptive Behavior using VABS-3 Composite and Domain Survey
大体时间：Baseline, Week 12, and Week 24
Change from baseline in adaptive functioning measured by the Vineland Adaptive Behavior Scales, Third Edition (VABS-3), including communication, daily living skills, socialization, and maladaptive behavior domains as reported by caregivers.
Baseline, Week 12, and Week 24
Change in Scores for Catatonia Severity using Bush-Francis Catatonia Rating Scale
大体时间：Baseline, Week 12, and Week 24

Change from baseline in catatonia symptoms measured by the Bush-Francis Catatonia Rating Scale (BFCRS), with decreases in total score indicating improvement in symptom severity.

0 (no catatonia) - 45 (Severe Catatonia)
Baseline, Week 12, and Week 24
Change in Score for Neuropsychiatric Symptoms using Neuropsychiatric Inventory Questionnaire (NPI-Q)
大体时间：Baseline, Week 12, and Week 24
Change from baseline in neuropsychiatric symptom burden as measured by the Neuropsychiatric Inventory Questionnaire (NPI-Q), a caregiver-reported assessment of symptom frequency and severity across behavioral domains.
Baseline, Week 12, and Week 24
Change in Motor Function (Timed 25-Foot Walk)
大体时间：Baseline, Week 12, and Week 24
Change from baseline in time (seconds) required to complete the Timed 25-Foot Walk (T25-FW), reflecting gait speed and motor function, with decreased time indicating improvement.
Baseline, Week 12, and Week 24
Change in Global Clinical Status Using Clinician Global Impression of Change-Down Syndrome (CGIC-DS)
大体时间：Baseline, Week 12, and Week 24
Change from baseline in global clinical status assessed using the Clinician Global Impression of Change-Down Syndrome (CGIC-DS), a Down syndrome-adapted clinician-rated instrument. The Baseline version generates a Clinical Global Impression-Severity (CGI-S) rating to assess overall illness severity, and the Follow-up version generates a Clinical Global Impression-Improvement (CGI-I) rating to assess clinical change relative to baseline. CGI-S scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill), while CGI-I scores range from 1 (very much improved) to 7 (very much worse). Assessments will be conducted at Baseline, Week 12, and Week 24.
Baseline, Week 12, and Week 24
Change in Global Clinical Status Using Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) Scores Derived from the Clinician Global Impression of Change-Down Syndrome (CGIC-DS)
大体时间：Baseline, Week 12, and Week 24
Change from baseline in global clinical status measured using CGI-S and CGI-I ratings derived from the Clinician Global Impression of Change-Down Syndrome (CGIC-DS). CGI-S assesses overall illness severity, and CGI-I assesses improvement or worsening relative to baseline. Assessments will be conducted at Baseline, Week 12, and Week 24. Lower CGI-S scores indicate reduced illness severity, and lower CGI-I scores indicate greater clinical improvement.
Baseline, Week 12, and Week 24
Change in Participant Quality of Life Using Pediatric Quality of Life Inventory (PedsQL) Parent Report
大体时间：Baseline, Week 12, and Week 24
Change from baseline in participant quality of life measured by the Pediatric Quality of Life Inventory (PedsQL) Parent Report. This caregiver-reported assessment evaluates health-related quality of life across physical functioning, emotional functioning, social functioning, and work/studies functioning domains. Higher scores indicate better quality of life and functional status. Assessments will be conducted at Baseline, Week 12, and Week 24.
Baseline, Week 12, and Week 24
Change in Caregiver and Family Functioning Using Pediatric Quality of Life Inventory Family Impact Module (PedsQL-FIM)
大体时间：Baseline to Week 24
Change from baseline in caregiver and family functioning measured by the Pediatric Quality of Life Inventory Family Impact Module (PedsQL-FIM). This caregiver-reported assessment evaluates the impact of the participant's condition on caregiver well-being and family functioning across physical, emotional, social, cognitive, communication, daily activities, and family relationship domains. Higher scores indicate better caregiver quality of life, improved family functioning, and less negative impact on the family. Assessments will be conducted at Baseline, Week 12, and Week 24.
Baseline to Week 24
Change in Communication Ability Using Observer-Reported Communication Ability (ORCA) Measure
大体时间：Baseline, Week 12, and Week 24
Change from baseline in communication abilities measured by the Observer-Reported Communication Ability (ORCA) Measure, a caregiver-reported assessment of expressive and receptive communication skills. The ORCA evaluates verbal communication, use of gestures, social communication, requesting, conversation, comprehension, and functional communication abilities in everyday settings. Higher scores indicate greater communication ability and improved functional communication.
Baseline, Week 12, and Week 24
Change in Caregiver and Family Functioning Using Pediatric Quality of Life Inventory Family Impact Module (PedsQL-FIM)
大体时间：Baseline, Week 12, and Week 24
Change from baseline in caregiver and family functioning measured by the Pediatric Quality of Life Inventory Family Impact Module (PedsQL-FIM). This caregiver-reported assessment evaluates the impact of the participant's condition on caregiver well-being and family functioning across physical, emotional, social, cognitive, communication, daily activity, and family relationship domains. Higher scores indicate better caregiver and family functioning and lower family burden.
Baseline, Week 12, and Week 24
Change in Obsessive-Compulsive Symptom Severity Using Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
大体时间：Baseline, Week 12, and Week 24
Change from baseline in obsessive-compulsive symptom severity measured by the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), a clinician-administered assessment of obsessions and compulsions. The CY-BOCS evaluates symptom severity across domains including time occupied, interference, distress, resistance, and degree of control. Higher scores indicate greater obsessive-compulsive symptom severity, and decreases in total score indicate improvement.
Baseline, Week 12, and Week 24

其他结果措施

结果测量
措施说明
大体时间
Change in Peripheral B-Cell Counts Following Ublituximab Treatment
大体时间：Baseline, Week 2, Week 6, Week 12, and Week 24
Change from baseline in peripheral B-cell populations measured by high-sensitivity flow cytometry, including absolute B-cell counts and percentages of CD19+ and CD20+ B cells. Exploratory analyses will evaluate the extent and duration of B-cell depletion following ublituximab treatment and the association between B-cell depletion and clinical outcomes.
Baseline, Week 2, Week 6, Week 12, and Week 24
Change in Inflammatory Cytokine Profiles
大体时间：Baseline and Week 24
Change from baseline in circulating inflammatory cytokine concentrations measured using multiplex immunoassay platforms. Cytokines and related inflammatory biomarkers will be evaluated to characterize immunologic changes associated with ublituximab treatment and Down Syndrome Regression Disorder (DSRD).
Baseline and Week 24
Change in Plasma Proteomic Signatures
大体时间：Baseline and Week 24
Change from baseline in plasma proteomic profiles measured using high-throughput proteomic platforms. Exploratory analyses will identify protein expression patterns associated with DSRD and evaluate molecular changes occurring following ublituximab treatment.
Baseline and Week 24
Change in Plasma Metabolomic Profiles
大体时间：Baseline and Week 24
Change from baseline in plasma metabolomic signatures measured using mass spectrometry-based metabolomic analyses. Exploratory analyses will evaluate treatment-associated changes in metabolic pathways and identify biomarkers associated with disease activity and therapeutic response.
Baseline and Week 24
Change in Interferon Signaling and Transcriptomic Profiles
大体时间：Baseline and Week 24
Change from baseline in whole-blood transcriptomic signatures, including interferon-related gene expression profiles, measured from RNA biospecimens. Exploratory analyses will characterize molecular pathways associated with DSRD and assess the impact of B-cell depletion therapy on interferon signaling and other transcriptional biomarkers.
Baseline and Week 24
Change in Global Autoantibody Profiles
大体时间：Baseline and Week 24
Change from baseline in circulating autoantibody profiles measured using high-throughput autoantibody profiling technologies. Exploratory analyses will evaluate changes in autoantibody repertoires following ublituximab treatment and assess associations wi
Baseline and Week 24
Change in Biomarkers of Neurodegeneration and Neuroinflammation
大体时间：Baseline and Week 24
Change from baseline in plasma biomarkers of neurodegeneration and neuroinflammation, including neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase L1 (UCHL1), total tau, and other validated biomarkers. Exploratory analyses will evaluate relationships between biomarker changes and clinical outcomes following ublituximab treatment.
Baseline and Week 24

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

Jonathan Santoro

调查人员

  • 首席研究员：Jonathan Santoro, MD、Children's Hospital Los Angeles

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2030年10月1日

研究完成 (估计的)

2030年12月1日

研究注册日期

首次提交

2026年9月4日

首先提交符合 QC 标准的

2026年9月4日

首次发布 (实际的)

2026年9月10日

研究记录更新

最后更新发布 (实际的)

2026年9月10日

上次提交的符合 QC 标准的更新

2026年9月4日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • CHLA-26-00158

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)？

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

订阅